Semax

Semax is described as a synthetic analog of the ACTH(4–10) fragment with a C-terminal Pro-Gly-Pro extension that increases metabolic stability. In the protocol’s mechanism section, Semax is presented as a neuroactive peptide that influences neurotrophic and neurotransmitter pathways relevant to cognition and recovery. Specifically, the page describes modulation of brain-derived neurotrophic factor (BDNF) expression, support of neuronal survival, and effects on monoaminergic systems; other sections discuss cholinergic and dopaminergic neurotransmission in the broader literature. Human use described in cited clinical work is primarily intranasal, including research in cognitive impairment and stroke recovery, but the protocol notes that subcutaneous administration can serve as a practical alternative with potentially more sustained systemic absorption that supports once-daily dosing. Overall, Semax is framed as a nootropic/neuroprotective peptide that supports neuroplasticity and resilience through BDNF-linked and monoamine-linked signaling.